Literature DB >> 15917565

In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.

Paul H Edelstein1, Baofeng Hu, Martha A C Edelstein.   

Abstract

LBM415 activity against extracellular and intracellular Legionella pneumophila was studied. The LBM415 MIC50 for 20 Legionella sp. strains was 4 microg/ml, versus 0.06, 0.25, and <or=0.03 microg/ml for azithromycin, erythromycin, and levofloxacin, respectively. LBM415 (0.5 and 16 microg/ml) reversibly prevented intracellular growth of two L. pneumophila strains and was less active than erythromycin.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917565      PMCID： PMC1140506          DOI： 10.1128/AAC.49.6.2533-2535.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

2.  In vitro activity of azithromycin against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Comparison of three buffers used in the formulation of buffered charcoal yeast extract medium.

Authors:  P H Edelstein; M A Edelstein
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

4.  In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; K H Lehr; J Ren
Journal:  J Antimicrob Chemother       Date:  1996-01       Impact factor: 5.790

5.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

6.  Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Thomas R Fritsche
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

7.  Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.

Authors:  Paul H Edelstein; William J Weiss; Martha A C Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191
  7 in total
  2 in total

1.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.